Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Anne Flament"'
Autor:
Caroline Lonez, Ahmad-Samer Al-Homsi, Dries Deeren, Nathalie Meuleman, Anne Flament, David E. Gilham, Taiga Nishihori, Marie-Sophie Dheur, Maher Abdul-Hay, Nathalie Braun, Erik Alcantar-Orozco, Gareth J. Morgan, Sébastien Anguille, Jason Brayer, Frederic Lehmann
Publikováno v:
Blood. 138:2817-2817
Off-the-shelf allogeneic CAR T cells derived from healthy donor cells have the potential to overcome many of the issues associated with the time-consuming manufacturing of autologous CAR T cells. However, adoptive transfer of allogeneic T cells carri
Autor:
Yves Beguin, David E. Gilham, Erik Alcantar-Orozco, Anne Flament, Caroline Lonez, Dries Deeren, Tara L. Lin, Nathalie Braun, Frederic Lehmann, Eytan Breman, Johan Maertens, Marie-Sophie Dheur
Publikováno v:
Blood. 138:408-408
While CAR T cell therapy has delivered impressive clinical efficacy in B cell malignancies, similar levels of clinical activity have not been demonstrated in acute myeloid leukemia (AML). One underlying reason for this lack of translation is the rela
Autor:
A. Samer Al-Homsi, Marie-Sophie Dheur, Nathalie Braun, Daniel A. Pollyea, David A. Sallman, Ine Moors, David E. Gilham, Anne Flament, William Blum, Frederic Lehmann, Erik Alcantar-Orozco, Philippe Lewalle, Caroline Lonez, Eytan Breman, Violaine Havelange, Marco L. Davila, Tessa Kerre, Xavier Poiré, Panagiota A. Sotiropoulou, Eunice S. Wang, Benjamin Demoulin
Publikováno v:
Blood. 136:40-41
Background CYAD-01 is a T-cell product engineered to express a chimeric antigen receptor (CAR) based on the NKG2D receptor (NKG2D CAR) which binds 8 ligands (MICA/B, ULBP1-6) over-expressed by a large variety of malignancies, including acute myeloid
Autor:
Panagiota A. Sotiropoulou, Frederic Lehmann, Laure Twyffels, Nathalie Meuleman, Anne Flament, Dries Deeren, Caroline Lonez, Nathalie Braun, Jason Brayer, Gareth J. Morgan, David E. Gilham, Taiga Nishihori, A. Samer Al-Homsi, Sébastien Anguille, Jennifer Bolsée
Publikováno v:
Blood. 136:27-28
Background Autologous CAR T-cell therapy targeting the B-cell maturation antigen (BCMA) has shown impressive objective response rates in patients with advanced multiple myeloma (MM). Clinical grade manufacturing of autologous CAR T-cells has limitati
Autor:
Johan Maertens, Frederic Lehmann, Yves Beguin, David E. Gilham, Marie-Sophie Dheur, Caroline Lonez, Dries Deeren, Panagiota A. Sotiropoulou, Anne Flament, Eytan Breman, Nathalie Braun, Tara L. Lin, Benjamin Demoulin, Martina Fontaine, Erik Alcantar-Orozco
Publikováno v:
Blood. 136:36-36
Background T-cells engineered to express a chimeric antigen receptor (CAR) based on the NKG2D receptor (NKG2D CAR) targeting the 8 NKG2D ligands (MICA/B, ULBP1-6) over-expressed by a large variety of malignancies have been developped to treat patient
Autor:
Fabian Borghese, A. Samer Al-Homsi, Anne Flament, Thomas Lequertier, Tessa Kerre, Caroline Lonez, Philippe Lewalle, Enkhtsetseg Purev, Maher Abdul-Hay, Daniel A. Pollyea, Ine Moors, Florence Renard, Erik Alcantar-Orozco, Adriano Salaroli, Nathalie Braun
Publikováno v:
BLOOD
CYAD-01 cells are engineered T-cells expressing a chimeric antigen receptor (CAR) based on the natural full-length human natural killer group 2D (NKG2D) receptor fused to the intracellular domain of CD3ζ. NKG2D binds to 8 ligands (MICA, MICAB, and U
Autor:
Nathalie Braun, Ine Moors, Anne Flament, Jason Brayer, Caroline Lonez, Erik Alcantar-Orozco, Ahmad Awada, Thomas Lequertier, Tessa Kerre, Kunle Odunsi, David A. Sallman, Xavier Poiré, Eunice S. Wang, Philippe Lewalle, Violaine Havelange
Publikováno v:
BLOOD
CYAD-01 cells are engineered T-cells expressing a chimeric antigen receptor (CAR) based on the natural full-length human natural killer group 2D (NKG2D) receptor fused to the intracellular domain of CD3ζ. NKG2D receptor binds to 8 ligands (MICA/B, U